Prix HBM Holdings Limited (2142.HK)

HBM Holdings Ltd. is an investment company, which engages in the discovery and development of differentiated antibody therapeutics in oncology and immunology disease areas. The company is headquartered in Suzhou, Jiangsu and currently employs 210 full-time employees. The company went IPO on 2020-12-10. The Company’s products primarily include BATOCLIMAB (HBM9161), HBM9378, HBM7020, TCE Program, PORUSTOBART (HBM4003), HBM7022 and others. The products are primarily used to treat generalized myasthenia gravis (gMG), chronic obstructive pulmonary disease (COPD), asthma, autoimmune diseases, melanoma, colorectal carcinoma (CRC) and solid tumors. The firm provides next-generation antibody and biotherapeutic solutions through proprietary antibody technology platforms including Harbour Mice, HBICE, HBICA and single B cell cloning platform.